Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients
ABSTRACT This study evaluated the BD Veritor system for rapid detection of SARS-CoV-2, an immunochromatographic point-of-care test, by comparing it with a standard reverse transcription-PCR (RT-PCR) methodology using samples from symptomatic patients. Samples from 146 symptomatic and 2 asymptomatic...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2022-10-01
|
| Series: | Microbiology Spectrum |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/spectrum.00190-22 |
| _version_ | 1811257718455926784 |
|---|---|
| author | Paula Koga Maira Maluf Fabiane Nunes Juliana Campos Lívia Gazarini Tatiane Borghoff Glaís Libanori Marinês Martino |
| author_facet | Paula Koga Maira Maluf Fabiane Nunes Juliana Campos Lívia Gazarini Tatiane Borghoff Glaís Libanori Marinês Martino |
| author_sort | Paula Koga |
| collection | DOAJ |
| description | ABSTRACT This study evaluated the BD Veritor system for rapid detection of SARS-CoV-2, an immunochromatographic point-of-care test, by comparing it with a standard reverse transcription-PCR (RT-PCR) methodology using samples from symptomatic patients. Samples from 146 symptomatic and 2 asymptomatic patients between the 1st and the 40th day of infection were evaluated. The nasopharyngeal and/or oropharyngeal swabs were inserted in a tube containing 0.9% saline solution and stored at refrigerator temperature until the moment of use. The samples were first tested with the Xpert Xpress SARS-CoV-2 (GeneXpert) kit (RT-PCR method), and the cycle thresholds (CTs) for the E and N2 genes encoding the SARS-CoV-2 envelope and nucleoprotein, respectively, were established. Subsequently, the same samples were tested using the Veritor rapid test. We analyzed the CTs of the N2 gene, which is detected in both methodologies, and observed sensitivities of 100%, 98.8%, 89.6%, and 82.7% for the CTs of <25, <27, and <30 and all the CTs, respectively. The greatest sensitivity was observed when we performed the test on patients within 5 days of symptom onset. The BD Veritor system’s workflow is simple and fast, taking approximately 16 min from sample preparation to obtaining the test result. In addition to its satisfactory sensitivity, with results that correlate with those of the RT-PCR, the BD Veritor analyzer instrument reduces the subjectivity of unaided visual readings and consequent potential variation in result interpretation. Therefore, our results showed that the BD Veritor diagnostic test can provide a rapid and accurate diagnosis for SARS-CoV-2. IMPORTANCE This study provides important and useful information, especially for diagnostic laboratories, since the results show that the BD Veritor system can provide a fast and safe point-of-care antigen diagnostic test for rapid detection of COVID-19 that has high sensitivity, reproducibility, and accuracy. |
| first_indexed | 2024-04-12T18:01:50Z |
| format | Article |
| id | doaj.art-e51e71b3c68741ba91ada874fd050f63 |
| institution | Directory Open Access Journal |
| issn | 2165-0497 |
| language | English |
| last_indexed | 2024-04-12T18:01:50Z |
| publishDate | 2022-10-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | Microbiology Spectrum |
| spelling | doaj.art-e51e71b3c68741ba91ada874fd050f632022-12-22T03:22:09ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972022-10-0110510.1128/spectrum.00190-22Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic PatientsPaula Koga0Maira Maluf1Fabiane Nunes2Juliana Campos3Lívia Gazarini4Tatiane Borghoff5Glaís Libanori6Marinês Martino7Clinical Laboratory Microbiology Department, Hospital Israelita Albert Einstein, São Paulo, São Paulo, BrazilClinical Laboratory Microbiology Department, Hospital Israelita Albert Einstein, São Paulo, São Paulo, BrazilClinical Laboratory Microbiology Department, Hospital Israelita Albert Einstein, São Paulo, São Paulo, BrazilBecton and Dickinson Company, BD Life Sciences – Integrated Diagnostic Solutions, São Paulo, São Paulo, BrazilBecton and Dickinson Company, BD Life Sciences – Integrated Diagnostic Solutions, São Paulo, São Paulo, BrazilBecton and Dickinson Company, BD Life Sciences – Integrated Diagnostic Solutions, São Paulo, São Paulo, BrazilBecton and Dickinson Company, BD Life Sciences – Integrated Diagnostic Solutions, São Paulo, São Paulo, BrazilClinical Laboratory Microbiology Department, Hospital Israelita Albert Einstein, São Paulo, São Paulo, BrazilABSTRACT This study evaluated the BD Veritor system for rapid detection of SARS-CoV-2, an immunochromatographic point-of-care test, by comparing it with a standard reverse transcription-PCR (RT-PCR) methodology using samples from symptomatic patients. Samples from 146 symptomatic and 2 asymptomatic patients between the 1st and the 40th day of infection were evaluated. The nasopharyngeal and/or oropharyngeal swabs were inserted in a tube containing 0.9% saline solution and stored at refrigerator temperature until the moment of use. The samples were first tested with the Xpert Xpress SARS-CoV-2 (GeneXpert) kit (RT-PCR method), and the cycle thresholds (CTs) for the E and N2 genes encoding the SARS-CoV-2 envelope and nucleoprotein, respectively, were established. Subsequently, the same samples were tested using the Veritor rapid test. We analyzed the CTs of the N2 gene, which is detected in both methodologies, and observed sensitivities of 100%, 98.8%, 89.6%, and 82.7% for the CTs of <25, <27, and <30 and all the CTs, respectively. The greatest sensitivity was observed when we performed the test on patients within 5 days of symptom onset. The BD Veritor system’s workflow is simple and fast, taking approximately 16 min from sample preparation to obtaining the test result. In addition to its satisfactory sensitivity, with results that correlate with those of the RT-PCR, the BD Veritor analyzer instrument reduces the subjectivity of unaided visual readings and consequent potential variation in result interpretation. Therefore, our results showed that the BD Veritor diagnostic test can provide a rapid and accurate diagnosis for SARS-CoV-2. IMPORTANCE This study provides important and useful information, especially for diagnostic laboratories, since the results show that the BD Veritor system can provide a fast and safe point-of-care antigen diagnostic test for rapid detection of COVID-19 that has high sensitivity, reproducibility, and accuracy.https://journals.asm.org/doi/10.1128/spectrum.00190-22SARS-CoV-2COVID-19rapid testsrapid antigen testPOC testVeritor test |
| spellingShingle | Paula Koga Maira Maluf Fabiane Nunes Juliana Campos Lívia Gazarini Tatiane Borghoff Glaís Libanori Marinês Martino Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients Microbiology Spectrum SARS-CoV-2 COVID-19 rapid tests rapid antigen test POC test Veritor test |
| title | Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients |
| title_full | Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients |
| title_fullStr | Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients |
| title_full_unstemmed | Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients |
| title_short | Comparison of the SARS-CoV-2 BD Veritor Nasal Antigen Test with Nasopharyngeal Reverse Transcription-PCR in Symptomatic Patients |
| title_sort | comparison of the sars cov 2 bd veritor nasal antigen test with nasopharyngeal reverse transcription pcr in symptomatic patients |
| topic | SARS-CoV-2 COVID-19 rapid tests rapid antigen test POC test Veritor test |
| url | https://journals.asm.org/doi/10.1128/spectrum.00190-22 |
| work_keys_str_mv | AT paulakoga comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients AT mairamaluf comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients AT fabianenunes comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients AT julianacampos comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients AT liviagazarini comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients AT tatianeborghoff comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients AT glaislibanori comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients AT marinesmartino comparisonofthesarscov2bdveritornasalantigentestwithnasopharyngealreversetranscriptionpcrinsymptomaticpatients |